C-GVJ1Repair Biotechnologies
cholesterol degradation, atherosclerotic plaque regression
clearingrna therapeutic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-GVJ1
C-GVJ1C-GVJ1cholesterol degradation, atherosclerotic plaque regression
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Repair Biotechnologies states that its Cholesterol Degrading Platform is a first-in-class therapeutic approach intended to reverse atherosclerosis, familial hypercholesterolemias, and other diseases where excess or modified cholesterol is a driver of pathology.
SourceRepair Biotechnologies states that its mission is to develop and bring to the clinic therapies that significantly improve human healthspan by targeting the causes of age-related diseases and aging itself. It further asserts that aging is a medical condition caused by accumulated molecular damage, and that because aging is damage, the appropriate therapeutic approach is repair.
SourceRepair Biotechnologies states that its purpose is to improve human healthspan by developing therapies that target the causes of age-related disease and aging itself. The company explicitly frames aging as a medical condition driven by accumulated molecular damage and argues that, because aging is damage, the correct therapeutic approach is repair.
SourceRepair Biotechnologies presented aging as something that can be meaningfully treated by repairing specific forms of age-related damage rather than only managing symptoms, with an initial focus on reversing immunosenescence and atherosclerosis through gene-therapy and recombinant-protein approaches. The company’s stated view was that restoring thymus function could renew T-cell production and improve age-related immune decline, and that selected rejuvenation therapies should be pushed from research into practical human medicine.
Source